MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  Ricciuti, Biagio ^a   Mecca, Carmen ^b   Cenci, Matteo ^a   Leonardi, Giulia Costanza ^a   Perrone, Lorenzo ^a   Mencaroni, Clelia ^a   Crino, Lucio ^a   Grignani, Francesco ^b   Baglivo, Sara ^a   Chiari, Rita ^a   Sidoni, Angelo ^b   Paglialunga, Luca ^a   Curra, Maria Francesca ^a   Murano, Emanuele ^a   Minotti, Vincenzo ^a   Metro, Giulio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

EGFR mutation; EGFR TKI; miRNAs; NSCLC; Resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MICRORNA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG MECHANISM; DRUG RESPONSE; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 84958769956     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.569     Document Type: Article

References (89)

1. Siegel R et al (2014) Cancer statistics, 2014 CA Cancer J Clin 64(1) 9-29 DOI: 10.3322/caac.21208 PMID: 24399786
2. Travis WD (2014) The 2015 WHO classification of lung tumors Pathologe 35(Suppl 2) 188 DOI: 10.1007/s00292-014-1974-3 PMID: 25394966
3. American Cancer Society Non-small cell lung cancer survival rates by stage Available at: http://cancer.org/cancer/lungcancernon smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates [accessed January 1, 2015]
4. Reck M et al (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25(suppl 3) iii27-39 DOI: 10.1093/annonc/mdu199 PMID: 25115305
5. Metro G and Crinó L (2012) Advances on EGFR mutation for lung cancer Transl Lung Cancer Res 1(1) 5-13 PMID: 25806150 PMCID: 4367583
6. Mok TS et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361(10) 947-57 DOI: 10.1056/NEJMoa0810699 PMID: 19692680
7. Fukuoka M et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29(21) 2866-74 DOI: 10.1200/JCO.2010.33.4235 PMID: 21670455
8. Han JY et al (2012) First-SIGNAL: first-line single-Agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 30(10) 1122-8 DOI: 10.1200/JCO.2011.36.8456 PMID: 22370314
9. Maemondo M et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362(25) 2380-8 DOI: 10.1056/NEJMoa0909530 PMID: 20573926
10. Inoue A et al (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatinpaclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) Ann Oncol 24(1) 54-9 DOI: 10.1093/annonc/mds214
11. Mitsudomi T et al Gefitinib versus cisplatin plus docetaxel in patient with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11(2) 121-8 PMID: 20022809
12. Yoshioka H et al (2014) Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) J Clin Oncol 32 (suppl 5; abstr 8117)
13. Zhou C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12(8) 735-42 DOI: 10.1016/S1470-2045(11)70184-X PMID: 21783417
14. Zhou C et al (2012) Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) J Clin Oncol 30 (suppl; abstr 7520)
15. Rosell R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13(3) 239-46 DOI: 10.1016/S1470-2045(11)70393-X PMID: 22285168
16. Sequist LV et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31(27) 3327-34 DOI: 10.1200/JCO.2012.44.2806 PMID: 23816960
17. Yang JC et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Lancet Oncol 16(2) 141-51 DOI: 10.1016/S1470-2045(14)71173-8 PMID: 25589191
18. Wu YL et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet Oncol 15(2) 213-22 DOI: 10.1016/S1470-2045(13)70604-1 PMID: 24439929
19. Mitsudomi T and Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer FEBS J 277(2) 301-8 DOI: 10.1111/j.1742-4658.2009.07448.x
20. Sibilia M et al (2007) The epidermal growth factor receptor: from development to tumorigenesis Differentiation 75(9) 770-87 DOI: 10.1111/j.1432-0436.2007.00238.x PMID: 17999740
21. Garrett TP et al (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha Cell 110(6) 763-73 DOI: 10.1016/S0092-8674(02)00940-6 PMID: 12297049
22. Burgess AW (2008) EGFR family: structure physiology signalling and therapeutic targets Growth Factors 26(5) 263-74 DOI: 10.1080/08977190802312844 PMID: 18800267
23. Mitsudomi T, Kosaka T and Yatabe Y (2006) Biological and clinical implications of EGFR mutations in lung cancer Int J Clin Oncol 11(3) 190-20 DOI: 10.1007/s10147-006-0583-4 PMID: 16850125
24. Sharma SV et al (2007) Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7(3) 169-81 DOI: 10.1038/nrc2088 PMID: 17318210
25. Murray S et al (2008) Somatic mutations of the tyrosine kinase domain of the epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database J Thorac Oncol 3(8) 832-9 DOI: 10.1097/JTO.0b013e31818071f3 PMID: 18670300
26. Wu JY et al (2011) Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer Clin Cancer Res 17(11) 3812-21 DOI: 10.1158/1078-0432.CCR-10-3408 PMID: 21531810
27. De Pas T et al (2011) Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations J Thorac Oncol 6(11) 1895-901 DOI: 10.1097/JTO.0b013e318227e8c6 PMID: 21841502
28. Yang JC et al (2013) Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer Oral presentation at: World Congress on Lung Cancer
29. Chiu CH et al (2015) Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations J Thorac Oncol 10(5) 793-9 DOI: 10.1097/JTO.0000000000000504 PMID: 25668120
30. Yang JC et al (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations J Clin Oncol 31(27) 3342-50 DOI: 10.1200/JCO.2012.46.1764 PMID: 23816967
31. Yang JC-H et al (2014) Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large openlabel phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) J Clin Oncol 32(Suppl):abstr 8004
32. Jackman D et al (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J Clin Oncol 28(2) 357-60 DOI: 10.1200/JCO.2009.24.7049
33. Wu JY et al (2008) Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib gefitinib tretment response Clin Cancer Res 14(15) 4877-82 DOI: 10.1158/1078-0432.CCR-07-5123 PMID: 18676761
34. Su KY et al (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer J Clin Oncol 30(4) 433-40 DOI: 10.1200/JCO.2011.38.3224 PMID: 22215752
35. Costa C et al (2014) The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial Clin Cancer Res 20(7) 2001-10 DOI: 10.1158/1078-0432.CCR-13-2233 PMID: 24493829
36. Yamamoto C et al (2010) Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-Activating mutations Cancer Res 70(21) 8715-25 DOI: 10.1158/0008-5472. CAN-10-0043 PMID: 20959484
37. Sos ML et al (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Cancer Res 69(8) 3256-61 DOI: 10.1158/0008-5472.CAN-08-4055 PMID: 19351834 PMCID: 2849653
38. Wang L et al (2014) PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup PLoS One 9(2) e88291 DOI: 10.1371/journal.pone.0088291 PMID: 24533074 PMCID: 3922761
39. Engelman JA et al (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFRamplified lung cancer J Clin Invest 116(10) 2695-706 DOI: 10.1172/JCI28656 PMID: 16906227 PMCID: 1570180
40. Ng KP et al (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer Nat Med 18(4) 521-8 DOI: 10.1038/nm.2713 PMID: 22426421
41. Costa C et al (2014) The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFRmutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial Clin Cancer Res 20(7) 2001-10 DOI: 10.1158/1078-0432.CCR-13-2233 PMID: 24493829
42. Ohashi K et al (2013) Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease J Clin Oncol 31(8) 1070-80 DOI: 10.1200/JCO.2012.43.3912 PMID: 23401451 PMCID: 3589701
43. Yun CH et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci USA 105(6) 2070-5 DOI: 10.1073/pnas.0709662105 PMID: 18227510 PMCID: 2538882
44. Maheswaran S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359(4) 366-77 DOI: 10.1056/NEJMoa0800668 PMID: 18596266 PMCID: 3551471
45. Balak MN et al (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin Cancer Res 12(21) 6494-501 DOI: 10.1158/1078-0432.CCR-06-1570 PMID: 17085664
46. Bean J et al (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma Clin Cancer Res 14(22) 7519-25 DOI: 10.1158/1078-0432.CCR-08-0151 PMID: 19010870 PMCID: 2596620
47. Nguyen KS, Kobayashi S and Costa DB (2009) Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway Clin Lung Cancer 10(4) 281-9 DOI: 10.3816/CLC.2009.n.039 PMID: 19632948 PMCID: 2758558
48. Engelman JA et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316(5827) 1039-43 DOI: 10.1126/science.1141478 PMID: 17463250
49. Yano S et al (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-Activating mutations Cancer Res 68(22) 9479-87 DOI: 10.1158/0008-5472.CAN-08-1643 PMID: 19010923
50. Yano S et al (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort J Thorac Oncol 6(12) 2011-7 DOI: 10.1097/JTO.0b013e31823ab0dd PMID: 22052230
51. Turke AB et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 17(1) 77-88 DOI: 10.1016/j.ccr.2009.11.022 PMID: 20129249 PMCID: 2980857
52. Sequist LV et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3(75) 75ra26 PMID: 21430269 PMCID: 3132801
53. Yu HA et al (2013) Analysis of tumour specimens at the time of acquired resistance to EGFR TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19(8) 2240-7 DOI: 10.1158/1078-0432.CCR-12-2246 PMID: 23470965 PMCID: 3630270
54. Thiery JP and Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions Nat Rev Mol Cell Biol 7(2) 131-42 DOI: 10.1038/nrm1835 PMID: 16493418
55. Suda K et al (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor mutant lung cancer cell line with acquired resistance to erlotinib J Thorac Oncol 6(7) 1152-61 DOI: 10.1097/JTO.0b013e318216ee52 PMID: 21597390
56. Zavadil J and Bottinger EP (2005) TGF-? and epithelial-to-mesenchymal transitions Oncogene 24(37) 5764-74 DOI: 10.1038/sj.onc.1208927 PMID: 16123809
57. Xie M et al (2012) Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib acquired resistant lung cancer cells J Cell Biochem 113(5) 1501-13
58. Zhang Z et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nat Genet 44(8) 852-60 DOI: 10.1038/ng.2330 PMID: 22751098 PMCID: 3408577
59. Yu HA et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19(8) 2240-7 DOI: 10.1158/1078-0432.CCR-12-2246 PMID: 23470965 PMCID: 3630270
60. Lin PY, Yu SL and Yang PC (2010) MicroRNA in lung cancer Br J Cancer 103(8) 1144-8 DOI: 10.1038/sj.bjc.6605901 PMID: 20859290 PMCID: 2967070
61. Krol J, Loedige I and Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay Nat Rev Genet 11(9) 597-610 PMID: 20661255
62. Qi J and Mu D (2012) MicroRNAs and lung cancers: from pathogenesis to clinical implications Front Med 6(2) 134-55 DOI: 10.1007/s11684-012-0188-4 PMID: 22528868 PMCID: 3725603
63. Grignani F et al (2014) Correlation of circulating miRNA levels with progression-free survival (PFS) and overall survival (OS) in early-stage lung adenocarcinoma J Clin Oncol 32 (suppl 5; abstr 11099)
64. Pan X, Wang ZX and Wang R (2010) MicroRNA-21 A novel therapeutic target in human cancer Cancer Biol Ther 10(12) 1224-32 DOI: 10.4161/cbt.10.12.14252 PMID: 21139417
65. Frezzetti D et al (2011) Upregulationof miR-21 by Ras in vivo and its role in tumor growth Oncogene 30(3) 275-86 DOI: 10.1038/onc.2010.416
66. Seike M et al (2009) MiR-21 is an EGFR-regulated antiapoptotic factor in lung cancer in never-smokers Proc Natl Acad Sci U S A 106(29) 12085-90 DOI: 10.1073/pnas.0905234106 PMID: 19597153 PMCID: 2715493
67. Li B et al (2014) MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer Lung Cancer 83(2) 146-53 DOI: 10.1016/j.lungcan.2013.11.003
68. Shen H et al (2014) Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer PLoS One 9(7) e103305 DOI: 10.1371/journal.pone.0103305 PMID: 25058005 PMCID: 4110008
69. Wang YS et al (2012) MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines Asian Pac J Cancer Prev 13(1) 255-60 DOI: 10.7314/APJCP.2012.13.1.255 PMID: 22502680
70. Cao M et al (2012) MiR-23a regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells Int J Oncol 41(3) 869-75 PMID: 22752005 PMCID: 3582905
71. Izumchenko E et al (2014) The TGF?-miR200-MIG6 pathway orchestrates the EMT-Associated kinase switch that induces resistance to EGFR inhibitors Cancer Res 74(14) 3995-4005 DOI: 10.1158/0008-5472.CAN-14-0110 PMID: 24830724 PMCID: 4122100
72. Kitamura K et al (2014) MiR-134/487b/655 cluster regulates TGF-?-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells Mol Cancer Ther 13(2) 444-53 DOI: 10.1158/1535-7163. MCT-13-0448
73. Cragg MS et al (2007) Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Med 4(10) 1681-9 DOI: 10.1371/journal.pmed.0040316 PMID: 17973573 PMCID: 2043013
74. Garofalo M et al (2011) EGFR and MET receptor tyrosine kinase-Altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers Nat Med 18(1) 74-82 PMID: 22157681 PMCID: 3467100
75. Zhou YM, Liu J and Sun W (2014) MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines Asian Pac J Cancer Prev 15(3) 1391-6 DOI: 10.7314/APJCP.2014.15.3.1391 PMID: 24606471
76. Acunzo M et al (2012) miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222 Oncogene 31(5) 634-42
77. Garofalo M et al (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation Cancer Cell 16(6) 498-509 DOI: 10.1016/j.ccr.2009.10.014 PMID: 19962668 PMCID: 2796583
78. Zhou JY et al (2014) MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET Cancer Lett 351(2) 265-71 DOI: 10.1016/j.canlet.2014.06.010 PMID: 24983493
79. Gomez GG, Wykosky J and Zanca C (2013) Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks Cancer Biol Med 10(4) 192-205 PMID: 24349829 PMCID: 3860350
80. Raver-Shapira N et al (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis Mol Cell 26(5) 731-43 DOI: 10.1016/j.molcel.2007.05.017 PMID: 17540598
81. Kasinski AL and Slack FJ (2012) miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma Cancer Res 72(21) 5576-87 DOI: 10.1158/0008-5472.CAN-12-2001 PMID: 22964582 PMCID: 3488137
82. Zhao J, Kelnar K and Bader AG (2014) In-depth analysis shows synergy between erlotinib and miR-34a PLoS One 9(2) e89105 DOI: 10.1371/journal.pone.0089105 PMID: 24551227 PMCID: 3925231
83. Mudduluru G et al (2011) Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer Oncogene 30(25) 2888-99 DOI: 10.1038/onc.2011.13 PMID: 21317930
84. Kaller M et al (2011) Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis Mol Cell Proteomics 10(8) M111.010462 DOI: 10.1074/mcp.M111.010462 PMID: 21566225 PMCID: 3149097
85. Gao Y et al (2014) miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124 Biochem Biophys Res Commun 446(1) 179-86 DOI: 10.1016/j.bbrc.2014.02.073 PMID: 24582749
86. Rai K et al (2011) Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells Mol Cancer Ther 10(9) 1720-7 DOI: 10.1158/1535-7163.MCT-11-0220 PMID: 21712475
87. Lee CG et al (2014) MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance PLoS One 9(1) e84597 DOI: 10.1371/journal.pone.0084597 PMID: 24454732 PMCID: 3893127
88. Chen JC et al (2014) Suppression of dicer increases sensitivity to gefitinib in human lung cancer cells Ann Surg Oncol 21(Suppl 4) 555-63 DOI: 10.1245/s10434-014-3673-y
89. Ricciuti B et al (2014) Non-coding RNAs in lung cancer Oncoscience 1(11) 674-705